Translational Scientific Advisory Board

David Cheresh, Ph.D.

Moores University of California, San Diego Cancer Center

Dr. Cheresh is a Distinguished Professor and Vice Chairman of Pathology at the University of California, San Diego (UCSD) School of Medicine and the Associate Director for Translational Research at the Moores UCSD Cancer Center. Dr. Cheresh is a leading authority in identifying key pathways and mediators of pathologic angiogenesis in tumors and has led efforts to develop new collaborations and programs in clinical and basic science with an emphasis on translational medicine. Dr. Cheresh serves as Associate Editor for several major scientific journals and is on the advisory board of several others. He is the recipient of several Visiting Professorship awards at universities worldwide, and has been honored with both The American Cancer Society’s Faculty Research Award and the Merit Award from the National Institutes of Health. Dr. Cheresh has more than 200 publications to his credit and his research is widely published, with seven papers cited more than 1,000 times each.

Dr. Cheresh received his doctorate in Immunology from the University of Miami School of Medicine and completed a postdoctoral fellowship in the Department of Immunology at The Scripps Research Institute.

Rakesh K. Jain, Ph.D.

Harvard Medical School, Massachusetts General Hospital

Dr. Jain is the Andrew Werk Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School, and Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital. He is regarded as a pioneer in the fields of tumor microenvironment, drug delivery, in vivo imaging and bioengineering, and is most well-known for proposing a new treatment principle—normalization of vasculature—for treatment of malignant and non-malignant diseases characterized by abnormal vessels that afflict more than 500 million people worldwide. His pioneering concept of normalization of pathologic neovascularization following anti-angiogenic therapy has provided the key scientific underpinnings for the development of Fovista in combination with anti-VEGF for wet AMD. Dr. Jain is on the Editorial Board of several major journals, including the Journal of Clinical Oncology, Nature Reviews Clinical Oncology and JAMA Oncology. He has worked as a consultant for many of the world’s top pharmaceutical and biotechnology companies, including Merck, Pfizer, Amgen, Novartis and Genzyme and currently serves on the Scientific Advisory Board of several Boston-based bioscience companies. Dr. Jain has been invited to lecture at hundreds of prestigious national and international conferences and seminars, Visiting Professorships and Universities worldwide. He is the author of more than 600 papers, served as editor for six books and holds six patents involving drug delivery and oncology practices. He is the recipient of numerous awards, most recently the Princess Takamatsu Memorial Lectureship Award from the American Association of Cancer Research (2014). In 2014, he was chosen as one of 50 Oncology Luminaries on the occasion of the 50th anniversary of the American Society of Clinical Oncology. Dr. Jain has the rare distinction of being a member of all three of the U.S. National Academies: the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

Dr. Jain received his B. Tech degree from the Indian Institute of Technology in Kanpur, India in Chemical Engineering. He went on to receive his Master of Sciences (M.S.) and Ph.D. in chemical engineering from the University of Delaware. After serving as assistant professor of chemical engineering at Columbia University he moved to Carnegie Mellon University in 1978, becoming a full professor of chemical engineering in 1983. In 1991, he moved to Harvard/MGH.